Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy

First Page		Document Content
Date: 2014-02-27 10:00:42 Head and neck cancer Otolaryngology Gynaecological cancer HPV-positive oropharyngeal cancer Cetuximab Human papillomavirus Panitumumab Papillomaviridae Epidermal growth factor receptor Medicine Oncology Papillomavirus		Impact of human papilloma virus infection on the response of head and neck cancers to anti-epidermal growth factor receptor antibody therapy Add to Reading List Source URL: www.nature.com Download Document from Source Website File Size: 1,50 MB Share Document on Facebook

	AbstractProspective multicenter phase II study of the anti-EGFR (epidermal growth factor receptor) antibody panitumumab (P) in patients with platinum pre-treated, advanced head and neck squamous cell cancer (HNSCC DocID: 1rVAJ - View Document
	UNIVERSITÄTSKLINIKUM Schleswig-Holstein Immuntherapie des Glioblastoms Sampson et al. - Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor DocID: 1rgeq - View Document
	Abstract ErbB2 overexpression gives rise to a highly invasive, aggressive phenotype associated with an enlarged lysosomal compartment and increased activity of the lysosomal proteases, cysteine cathepsins. We have recent DocID: 1rdcC - View Document
	Wrangling Phosphoproteomic Data to Elucidate Cancer Signaling Pathways Mark L. Grimes1*, Wan-Jui Lee2, Laurens van der Maaten2, Paul Shannon3 1 Division of Biological Sciences, University of Montana, Missoula, Montana, U DocID: 1qMPs - View Document
	ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced DocID: 1qm1i - View Document